GRAIL, Inc. (GRAL) Dividend History

Company News

• Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

  Quest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.

  Benzinga

  Featured Companies: DGX
• Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock

  Jim Cramer recommends buying GRAIL and considers Healthpeak Properties a 'reasonable' REIT. He also discusses his views on other healthcare and technology stocks.

  Benzinga

  Featured Companies: ANET DOC EW RBRK SHAK SQ TMDX XYZ
• Investors Eye Biotech Sector as Cancer Therapy Market Surges

  The global cancer therapy market is expected to grow significantly, driven by advancements in cancer detection and treatment technologies. Several biotech companies, including Oncolytics Biotech, GRAIL, Quest Diagnostics, Renovaro, and Predictive Oncology, have made notable progress in their respective cancer-focused initiatives.

  Benzinga

  Featured Companies: DGX ONCY POAI RENB
• European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine

  The European Court of Justice ruled in favor of Illumina, stating that the European Commission exceeded its authority by asserting jurisdiction over Illumina's acquisition of GRAIL. The $476.96 million fine will no longer be payable, and the U.S. FTC also dismissed the case against Illumina and GRAIL.

  Benzinga

  Featured Companies: ILMN